



2025 Year in Review

Michigan Collaborative for Type 2 Diabetes



In 2025, the Michigan Collaborative for Type 2 Diabetes (MCT2D) delivered results on its first statewide performance measure aimed at improving A1C control. Across 340 participating primary care practices, performance improved by an absolute 1% for Medicare patients and by an absolute 2% for Commercial patients from baseline.

MCT2D expanded to include an additional performance measure for primary care physicians, as well as initial performance measures for endocrinologists and nephrologists. This year, MCT2D led new, innovative programs, including kicking off the development of our prediabetes initiative, launching the first-ever MCT2D low carb counseling workshop, and conducting our first set of site visits to eight practices across Michigan.

Finally, we shared high-impact tools, including publishing our work on developing the MCT2D Coverage Checker in the Annals of Family Medicine.

This annual report is our 2025 season recap: performance measures launched, partnerships strengthened, and a statewide team proving that when we improve together, progress in type 2 diabetes care is measurable, shared, and built to last.

Our Impact



550+

Additional Michigan patients achieved A1C control

As defined by HEDIS target rates

96.2%

Medicare patients met target

86.1%

Commercial patients met target

Our Team

371

Primary Care Practices

26

Endocrinology Practices

14

Nephrology Practices

1,275

PCPs

91

Endocrinologists

88

Nephrologists

PERFORMANCE MEASURES

Our 2025 performance measures are the foundation of MCT2D's collaborative quality improvement approach, establishing clear benchmarks that drive meaningful clinical outcomes across Michigan.



Primary Care A1C

MCT2D is entering a second year working to improve A1C, increasing target rates by ~4% to align with newly updated HEDIS 90th percentile rates.

Target:

Commercial (A1C <8): 74.45%
Medicare (A1C \leq 9): 91%

Performance Period: 7/1/2025-4/30/2026



Primary Care uACR Screening

MCT2D added a second primary care measure aimed at increasing annual uACR screening, a critical component of early kidney disease detection.

Target:

10% absolute improvement in screening rates over 14 months

Performance Period: 7/1/2025-8/31/2026



Endocrinology CGM Interpretation

Endocrinology practices are focusing on the download, interpretation, and integration of CGM data into care plans to ensure optimal clinical outcomes.

Target:

5% increase in documented CGM interpretation codes

Performance Period: 7/1/2025-8/31/2026



Nephrology uACR Screening

In alignment with primary care efforts, nephrology practices are working towards increasing uACR screening rates for timely kidney disease intervention.

Target:

5% absolute improvement over 14 months

Performance Period: 7/1/2025-8/31/2026



MAJOR PROJECTS 2025



Each project represents months of dedication, planning, and expert execution by our championship team.

Low Carb Workshops



Developed two weeklong educational workshops on low carbohydrate diet for clinicians. Thirty-seven MCT2D members participated.

"...after taking the [LCD workshop], I have more comfort and knowledge behind me to have that discussion with a patient."

— RN Care Manager, Workshop Participant

MCT2D Mobile App



Launched our first mobile application, providing physicians with on-the-go access to MCT2D's comprehensive tool library, coverage checker, and latest news updates.

Point-of-care resources, Coverage Checker Lite, and event registration—now on iOS and Android.

380+
Downloads

5★
Rating

90%+
Retention

First Site Visits

Conducted site visits at eight participating practices to deepen connections, understand real-world workflows, and support practices in addressing implementation challenges.



Prediabetes Initiative

Building a comprehensive platform with tools, education, and resources to prevent progression to diabetes.



✓ Patient Education

✓ Provider Resources

✓ Interactive Tools

✓ Prevention Plans

TOOLS, INNOVATION & COLLABORATION

Tools & Publications

2025 MCT2D Clinical Tools



New tools include:

uACR Patient and Provider Handouts
Maintaining Your Muscle Health
Prediabetes Screening Guide
CGM Ordering Guide

22,862

Digital Tool Downloads

32,200+

Print Tools Distributed

Annals of Family Medicine

MCT2D published an article in the Annals of Family Medicine highlighting our collaborative design process and the development of our widely used coverage checker tool.


Kim, N., Cardinal, S., Gabison, J., Oshman, L., Rau, J., Reiss, J., Young, L., & Diez, H. L. (2025). **Coverage checker: A web-based tool to navigate diabetes coverage and prior authorization.** The Annals of Family Medicine, 23(4), 378–378. <https://doi.org/10.1370/afm.240633>

PAB & Data Dashboard

Patient Advisory Board (PAB)

Convening six times each year, our Patient Advisory Board continues to be instrumental in shaping MCT2D's tools, resources, and programs with real-world patient perspectives.

"The fact that we're meeting here now, as patients speaking with clinicians and health care professionals and you are hearing directly from us is a big step."



-PAB member, Larry Davis
May 2025

Data Dashboard Enhancements

Launched comprehensive dashboard updates providing real-time insights into practice performance and patient outcomes.

Claims data for 245,325 patients ✓

Medicaid claims added in 2025 ✓

NEW Data Completeness & Trends Reports ✓

Endocrinology Attribution ✓

MCT2D 2026 GOALS

The race continues! Our sights are set on even greater achievements in the year ahead.

Q1-Q2 2026

Launching MCT2D Prediabetes Initiative

Creating a comprehensive prediabetes web platform for patients and providers with prevention resources and lifestyle management tools.

Q2-Q4 2026

Improving Member Experience

Redesigning our MCT2D Admin Portal to better support users with enhanced navigation, streamlined workflows, and improved functionality.

Q2-Q3 2026

Further Patient Data Dashboard Improvements

Completing Dashboard 2.0 with patient lists and patient profile views for more granular performance insights and clinical decision support, as well as prepopulated reports.

Q1-Q4 2026

Site Collaboration and Support

Expanding efforts to support MCT2D practices including adding more site visits, practice-to-practice learning opportunities, workshops, certifications, and T2D education.

Q2-Q3 2026

Developing New Patient Tools

New handouts on insulin use, videos on uACR screening, and education on low carb diets.

Q3 2026

Expanded Performance Metrics

Launching additional performance measures to improve the health of patients with T2D.

OUR TEAM

Lynn Ang, MBBS
Neha Bhomia, MHI
Heidi L. Diez, PharmD, BCACP
Jonathan Gabison, MD
Dina Hafez Griauzde, MD, MS
Michael Heung, MD, MS
Rina Hisamatsu, MPH, RDN

Jennifer Iyengar, MD
Noa Kim, MSI
Amy Kuehls
Kit Lam, BS
Joyce Lee, MD, MPH
Aleda Leis, PhD, MS
Kara Mizokami-Stout, MD, MS
Lauren Oshman, MD, MPH

Katie Pascoe, BS
Jackie Rau, MHSA, PMP
Jake Reiss, MHSA
Julian Weisensel, BFA
Julie Wright Nunes, MD, MPH
Lypha Yang, BS



Support for The Michigan Collaborative for Type 2 Diabetes (MCT2D) is provided by Blue Cross Blue Shield of Michigan as part of the BCBSM Value Partnerships program.